Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Breathlessness Perceptions Within Respiratory Diseases (BiRD)

10. Juni 2026 aktualisiert von: University Hospitals, Leicester

Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases

Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.

Studienübersicht

Detaillierte Beschreibung

Breathlessness is a debilitating symptom that results in poorer quality of life, increased hospitalisations, and increased mortality. Breathlessness is a complex multi-dimensional sensation with established bio-psycho-social influences (Hayen et al., 2013) that are likely to interact, though the mechanisms or relative contributions of these interactions are unknown (Oxley & Macnaughton, 2016). Breathlessness is a hallmark feature of respiratory disease and is the primary reason for seeking healthcare advice and treatments. Though currently breathlessness management follows a one-size fits all approach and does not pay consideration to the unique and individual experience of breathlessness.

The breathing thinking functioning (BTF) model of breathlessness is a theoretical framework that attempts to explain this complex and multifactorial symptom, however it lacks scientific premise. Highlighting that physiology, psychology and function will all play a role in determining breathlessness for the individual. An additional complication, that is seldom explored is disordered breathing patterns. This is potentially bi-directional where by severe breathlessness could contribute to disordered breathing and/or disordered breathing could lead to severe breathlessness. There is currently no objective marker of disordered breathing pattern however, use of optoelectronic plethysmography (OEP) has shown promise in quantifying this phenomenon (Smyth, 2021). OEP is a novel technique, utilising 3-dimensional motion capture, and can be measured during exercise, using a cardiopulmonary exercise testing, which allows for monitoring of breathlessness and breathing pattern during exercise, commonly reported as troublesome by patients. OEP has been used in Chronic Obstructive Pulmonary Disease to assess hyperinflation, though evidence within respiratory disease is at its infancy, and has not been explored alongside other factors to understand the contribution of multiple factors of breathlessness. Therefore, there is a current gap in the literature exploring the interaction(s) of factors contributing to breathlessness severity, including the objective analysis of breathing pattern. Further understanding the breathlessness in this way could lead to personalisation or treatments increasing their effectiveness, and improving health and quality of life. The project will quantitatively measure breathlessness perception, alongside objective cardiorespiratory measures and background health and well-being data as well as OEP breathing pattern data (such as compartment contribution and inter-compartment asynchrony). This will allow an understanding of how each of these factors may affect interventions and differences in breathlessness experience and presentation, and subsequently the acceptability of breathlessness.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

75

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Enya Dr. Daynes, PhD
  • Telefonnummer: +44 0116 273 0333
  • E-Mail: e.daynes@nhs.net

Studieren Sie die Kontaktsicherung

Studienorte

    • Leicestershire
      • Leicester, Leicestershire, Vereinigtes Königreich, LE3 9QP
        • Rekrutierung
        • Glenfield Hospital
        • Kontakt:
        • Hauptermittler:
          • Enya Daynes, PhD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population consists of a healthy group and a disease group. The disease group will have a known respiratory condition such as COPD, Asthma, ILD or Bronchiectasis. The healthy group will not have any functionally limiting conditions interms, cardiorespiratory and muskuloskeletal.

Beschreibung

Inclusion Criteria:

  • • Aged 18 or over up to 100

    • Known respiratory diagnosis* OR Healthy control**
    • Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale
    • Able to communicate in English
    • Able to attend two study visits
    • Able to provide written informed consent

      • Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.
      • Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.

Exclusion Criteria:

  • • Unstable disease or undergoing investigations for unexplained symptoms

    • Undergone a surgery within past six weeks
    • Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)
    • BMI ≥ 35kg/m2
    • Unable to communicate in English
    • Unable to provide written informed consent
    • Unable to abstain from smoking for 8 hours prior to testing

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
50 participants with a respiratory disease and 25 health controls will be recruited.

Inclusion criteria is:

  • Aged 18 or over up to 100
  • Known respiratory diagnosis* OR Healthy control**
  • Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale
  • Able to communicate in English
  • Able to attend two study visits
  • Able to provide written informed consent

    • Known respiratory diagnosis could include, but is not limited to, Chronic Obstructive Pulmonary Disease, Asthma,Bronchiectasis or Interstitial Lung Disease.

      • Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.

Participants are excluded if,:

  • Unstable disease or undergoing investigations for unexplained symptoms
  • Undergone a surgery within past six weeks
  • Contraindications for exercise outlined by American College of Sports Medicine guidelines (Unstable Cardiovascular disease, hypertension etc)
  • Body Mass Index ≥ 35kg/m2
  • Unable to communicate in English
  • Unable to provide consent

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Breathing pattern regional contribution parameters
Zeitfenster: From June 2025 to July 2026
Optoelectronic plethysmography allows to quantify how different thoracic compartments contribute to the overall tidal volume through regional contribution parameters. These regional contributions are expressed as percentages.
From June 2025 to July 2026

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Breathing pattern-Timing parameters-Recording duration
Zeitfenster: From June 2025 to July 2026
The duration will be recorded in minutes and seconds to state how long a specific measurement lasted.
From June 2025 to July 2026
Breathing pattern-Timing parameters- Sampling frequency rate
Zeitfenster: From June 2025 to July 2026
This is one of the core timing parameter. The system uses sample at 60-120 Hz (frames per second).
From June 2025 to July 2026
Breathing pattern-Timing Parameters- Number of respiratory cycles analysed
Zeitfenster: From June 2025 to July 2026
This parameter is important to give an indication of data adequacy. It will be reported in whole numbers.
From June 2025 to July 2026
Breathing pattern-Ratio parameters-Compartmental contributions
Zeitfenster: From June 2025 to July 2026
All the parameters will be expressed as percentages. (%RCp, %RCa and %AB) typically ranging from (0-100%)
From June 2025 to July 2026
Breathing pattern- Phase angle parameters
Zeitfenster: From June 2025 to July 2026
These parameters will be meausred by the degree ranging from 0 to 180 (Complete paradox)
From June 2025 to July 2026
Breathing pattern-ratio parameters- Temporal ratios
Zeitfenster: From June 2025 to July 2026
This will be reported in decimal values. (Ti/Ttot, Ti/Te ratio, IE ratio inverse of Ti/Te) Ti-Inspiratory time Te-Expiratory time Ttot-Total breath duration
From June 2025 to July 2026
Rate of Perceived Exertion (RPE) and Borg breathlessness scale
Zeitfenster: From June 2025 to July 2026
Provides details about how breathlessness one feels and how hard the exercise is during exercise . Both these scales will be reported in numbers. The RPE is from 6-20 and the Borg scale is from 0-10. Higher scores will indicate worst breathlessness and exertion from the performing exercise.
From June 2025 to July 2026
Spirometry
Zeitfenster: From June 2025 to July 2026
Lung Function parameters such as FEV1 -Forced Expiratory Volume, FVC -Forced Vital Capacity, FEV1/FVC ratio will be obtained using Spirometry (Spirotrac). Presented in litres can be converted to percentage. Depending on the guidelines usually if the FEV1/ FVC ratio<= 0.7 it can be said that there is an airway obstruction. Lower value indicates a higher level of breathlessness. The GOLD classification criteria is usually used to describe the severity. The values can further be explained as obstructive or restrictive by looking at the FVC%. A lower FVC% predicted will indicate worse restriction.
From June 2025 to July 2026
Modified Medical Research Council Dyspnea Scale (mMRC)
Zeitfenster: From June 2025 to July 2026
Scale that grades the severity of breathlessness based on the level of physical activity that provokes the symptom. The scale is from 0-4. Lower values indicate less severity of breathlessness while higher values indicate severe breathlessness.
From June 2025 to July 2026
Dysponea-12 (D-12)
Zeitfenster: From June 2025 to July 2026
The Dyspnoea-12 (D-12) is a patient-reported outcome measure designed to assess the multidimensional nature of breathlessness severity through both physical and affective components. The questionnaire has 12 questions where the participant will be asked to put a tick to any box from none, mild, moderate and severe.
From June 2025 to July 2026
Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: From June 2025 to July 2026
Self-report questionnaire designed to screen for clinically significant anxiety and depression in medical populations. The participant will be asked to underline their answers for all the questions. The questionnaire includes a 'A' category and a 'D' category. Scores are given to both catergories from 0-3. At the end the two catergoeies will be calculated separately.
From June 2025 to July 2026
Breathlessness catastrophising scale (BCS)
Zeitfenster: From June 2025 to July 2026
A measure designed to assess catastrophic thinking patterns specifically related to breathlessness. BCS is a 13 item questionnaire where the participant will have to tick one of the boxes for each question starting from not at all, to a slight degree, to a moderate degree, to a great degree and all the time.
From June 2025 to July 2026
Euroqol 5-Domain-5-Level (EQ5D-5L)
Zeitfenster: From June 2025 to July 2026
A standardised generic health-related quality of life instrument designed to provide a simple, comprehensive measure of health status across diverse populations and conditions. The questionnaire asseses 4 sections where the participant will have to select one option from each section. The questionnaire is assessing the health related quality of life interms of that day and not in general. At the end of the questionnaire there is a separate scale from 0-100 where the participant will have to place an x mark on the scale and write that score in a box which will indicate how they feel on that specific day.
From June 2025 to July 2026
Nijmegen Questionnaire (NQ)
Zeitfenster: From June 2025 to July 2026
An instrument designed to assess symptoms associated with hyperventilation syndrome and dysfunctional breathing patterns. The questionnaire contains 16 symptoms. The participant will be required to place a tick in one of the boxes for each question. Answers include, never, rarely, sometimes, often and very often.
From June 2025 to July 2026
Breathing pattern assessment tool (BPAT)
Zeitfenster: From June 2025 to July 2026
Visible characteristics of breathing patterns during rest where the participant will be asked to rest against a back seat. The participant will be observed for 1 minute by a member of the study team where they will have to breathe in and out as they usually do. During that time the team member will observe whether the breathing is rhythmical, whether the participant is using using their chest, abdomen or both for breathing, whether their inspiratory and expiratory flows are silent, audible or loud. Other questrions that will be answered by the team member would be channel of inspiration and expiration, air hunger, rhythm as well the team member will also calculate the respiratory rate within a 1 minute. Scores will be given from 0-2 and at the end the total score will be calculated.
From June 2025 to July 2026
Cardiopulmonary Exercise testing -Gas Exchange Parameters
Zeitfenster: From June 2025 to July 2026

Peak Oxygen Uptake (VO2 peak) meausured through mL/min or L/min, If >=85 is normal, 65-84 is mildly reduced, 50-64 is moderately reduced and <50 is severely reduced.

Carbon Dioxide Output (VCO2) and RER (VCO2/VO2) meausured through mL/min or L/min, VCO2 roughly rises parallel to VO2. The volume of CO₂ produced per minute by the body reflects the metabolic CO₂ production from aerobic and anaerobic metabolism combined. The respiratory exchange ratio which is RER gives a clear indication whether the test was maximal effort or not.

RER >=1.10 is the key cutoff.

AT will all be meausured through mL/min or L/min. Normal: typically > 40% of predicted VO₂ max, or ≥ 11 ml/kg/min Higher AT = better - indicates the body can sustain aerobic metabolism at higher workloads before switching to anaerobic system.

From June 2025 to July 2026
Cardiopulmonary Exercise Testing- Ventilatory Parameters (Minute Ventilation)
Zeitfenster: From June 2025 to July 2026
Minute Ventilation will be measured at maximal exercise. The measures will be stated in L/min. Minute ventilation is assess the ventilatory capacity. Usually the ventilatory reserve utilizes <60 to 70% of the maximum voluntary ventilation which is considered healthy.
From June 2025 to July 2026
Cardiopulmonary Exercise Testing- Ventilatory Parameters (Tidal Volume)
Zeitfenster: From June 2025 to July 2026
Tidal Volume will be measured by L or mL. It is amount of air that moves in and out of the lung. During exercise, it increases linearly before plateauing indicating whether a participant's exercise capacity is physically restricted due to lung mechanics.
From June 2025 to July 2026
Cardiopulmonary Exercise Testing- Ventilatory Parameters ( Respiratory Rate)
Zeitfenster: From June 2025 to July 2026

This is measured by breaths per minute. The amount of breaths taken will indicate how your brain and lungs are functioning to clear the carbondioxide which will help to maintain the chemical balance.

Resting phase 12 to 20 breaths/min -Baseline range Peak Exercise 35 to 45 breaths/min -Normal physiological range for healthy adults.

From June 2025 to July 2026
Cardiopulmonary Exercise Testing-Ventilatory Parameters (MVV and BR)
Zeitfenster: From June 2025 to July 2026
MVV- Maximal Voluntary Ventilation and BR-Breathing Reserve both are measured by L/min. This determines whether a patient's exercise capacity is limited by their lungs or by their heart and/or muscles. MVV represents a participants absolute ceiling for breathing capacity, while BR measures how much of that capacity is left over at peak exercise. If MVV >=80% it is considered good and if <80% it is considered bad. Whereas for BR, if >11L/min is considered as the lungs still having more capacity left after exercising and <=11L/min is considered that the patient is exhausted and their breathing capacity has reached the limit.
From June 2025 to July 2026
Cardiopulmonary Exercise Testing- Ventilatory Efficiency Parameters
Zeitfenster: From June 2025 to July 2026
VE/VO2 slope and VE/VCO2 at AT are measured by a dimensionless ratio. VE/VCO2 is considered good when it is between 23-30 and bad when it is >34. VE/VO2 is considered good when it is between 25 to 33 and bad when it is >36
From June 2025 to July 2026
Cardiopulmonary Exercise Testing-HR reserve
Zeitfenster: From June 2025 to July 2026
This will be measured through bpm. It is the difference between predicted maximum heart rate and the actual peak heart rate. <15bpm indicates a good response whereas >=15bpm indicates a poor response.
From June 2025 to July 2026
Cardiopulmonary Exercise Testing- Work Rate
Zeitfenster: From June 2025 to July 2026
This will be reported in W (Watts). Achieving >= 80% of the predicted work rate is considered a good response whereas <80% would be considered as a poor response.
From June 2025 to July 2026
Oxygen Saturation
Zeitfenster: From June 2025 to July 2026
This will be reported through % (Percentage). 95-100%- Good 93-94%- Borderline <92%- Bad
From June 2025 to July 2026
Blood pressure
Zeitfenster: From June 2025 to July 2026

This will be measured by mmHg Before the test (At rest) >=200/110- Contraindication not to perform the exercise test <90/60- Too low for the baseline

During the exercise test, If the systolic value exceeds 190 or 210 indicates a severe hypertension A critical stop would be a systolic value exceeding 250 or a diastolic value exceeding 115.

After the test, The blood pressure should return to near or actual borderline taken during rest.

From June 2025 to July 2026
Height
Zeitfenster: From June 2025 to July 2026
Measured through cm.
From June 2025 to July 2026
Weight
Zeitfenster: From June 2025 to July 2026
Measured by kg (Kilograms).
From June 2025 to July 2026
Body Mass Index
Zeitfenster: From June 2025 to July 2026
Calculated manually via height and weight measurements. Will be presented as kgm squared. This study has a cut off value which is not involving participants above 35.
From June 2025 to July 2026
Heart rate variability (HRV) - Holter Monitor
Zeitfenster: From June 2025 to May 2026
SDNN- Standard Deviation of normal-to-normal R-R intervals, SDANN-Standard Deviation of the mean R-R intervals, RMSSD-Square root of the mean squared difference of successive R-R intervals are all measued by milliseconds (ms).
From June 2025 to May 2026
Heart Rate Variability-Holter Monitor
Zeitfenster: From June 2025 to July 2026

LF-Low Frequency Power and HF-High Frequency Power are both measured by milliseconds squared or absolute units.

LF Absolute 300 to 1500- considered good LF Absolute <100 -considered bad/abnormal

HF Absolute 200 to 1000- considered good HF Absolute <50- considered bad/abnormal

From June 2025 to July 2026
Heart Rate Variability-Holter Monitor
Zeitfenster: From June 2025 to July 2026

LF/HF ratio will be a dimensionless ratio represented without any units. High rates will suggest of sympathetic predominance.

At rest Good range will be 1.0-2.0 Bad range >5 or <0.5

From June 2025 to July 2026

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Enya Daynes, PhD, University Hospitals, Leicester

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

6. Juni 2025

Primärer Abschluss (Geschätzt)

1. Juli 2026

Studienabschluss (Geschätzt)

1. Juli 2026

Studienanmeldedaten

Zuerst eingereicht

31. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Juni 2026

Zuerst gepostet (Tatsächlich)

15. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

15. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Once participnats enrolled the data were anonymised. All the outcome measure data will be made available and kept within a locked UHL cabnited and password protected computer for future study purposes.

IPD-Sharing-Zeitrahmen

Start Date -June 2025 to June 2030

IPD-Sharing-Zugriffskriterien

The study team will be able to access the data.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren